A recent study indicates that people who stop using new GLP-1 drugs like semaglutide or tirzepatide tend to recover lost weight far faster than those who stop traditional diet and exercise plans.
Findings released in a major medical journal shows that while obese people frequently drop about a fifth of their total mass while using the jabs, the mass is regained at an average rate of 0.8 kg per month once they quit.
"People purchasing such drugs should be informed of the risk of fast rebound weight gain when the treatment ends," stated researcher Dr. Susan Jebb.
That rate of recovery suggests a reversion to pre-treatment mass in about 18 months.
Comparing Therapies
The research, which reviewed 37 of studies involving over 9,000 of participants, contrasted the effects of the injectable medications with conventional dieting.
The team note that people who shed pounds through dieting typically see a less rapid creep back—approximately 100 grams monthly—after stopping.
The Reason for the Rapid Regain
Experts propose the mode of action of the injections accounts for the amplified regain.
GLP-1 drugs imitate a body's own chemical called glucagon-like peptide-1, which controls hunger.
"Artificially providing GLP-1 concentrations several times higher than the body's typical production could lead to the body to generate a reduced amount of its own natural GLP-1, and could diminish responsiveness to its effects," explained Dr. Adam Collins, a dietetics researcher.
"Withdrawal of this hormone supplement means hunger is unsuppressed, making overeating much more probable."
A Lifelong Disease?
The NHS advise the jabs for individuals with weight-linked health risks, alongside recommended lifestyle changes.
A number of clinicians say that, given the high risk of weight regain, the therapy should be considered long-term.
This perspective is echoed by drug manufacturers, who state that the findings "underscore the chronic nature of excess weight," akin to managing diseases like hypertension.
User Experiences
Individuals who have discontinued the jabs report a powerful resurgence of appetite.
"It was like something activating and I was suddenly starving," said a patient.
This challenge is compounded if users have not developed permanent dietary or behavioural changes during treatment.
Growing Adoption
Survey data show that millions of adults in the UK have tried weight-loss jabs in the past year, with desire being substantial.
- Use is more common among women compared to men.
- The 40s and 50s demographic shows the highest usage rates.
- A large proportion obtain the medications through private prescriptions rather than the NHS.
In conclusion, researchers caution that while GLP-1 drugs are potent tools for weight loss, they are not a standalone solution and lasting health benefits hinges on integrated behavioural management.
